Last updated on August 2018

Combined Alternating Sunitinib and Bevacizumab (Avastin ) in Advanced Renal Cell Carcinoma (CASA)


Brief description of study

Combined sunitinib and bevacizumab in advanced renal cell carcinoma.

Detailed Study Description

This is a phase I/II trial of combined sunitinib and bevacizumab in advanced renal cell carcinoma ( CASBA) where Bevacizumab will be used only on day 29 of each 6 weeks sunitinib cycle.

Clinical Study Identifier: NCT02919371

Find a site near you

Start Over